{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:22:50Z","timestamp":1787660570109,"version":"build-2736575974"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijgc.2026.104944","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:49:10Z","timestamp":1785826150000},"page":"104944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does timing matter? Rethinking immunotherapy strategies in locally advanced cervical cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0878-0876","authenticated-orcid":false,"given":"J\u00falia Chain","family":"Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Gabriela","family":"Gomes Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia","family":"de Mello Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Scaranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5966-8940","authenticated-orcid":false,"given":"Let\u00edcia Vecchi","family":"Leis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10434","key":"10.1016\/j.ijgc.2026.104944_bib1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104944_bib2","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol [Internet]"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104944_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100070","article-title":"Academic randomized phase II trial assessing the inhibitor of programmed cell death ligand 1 (PD-L1) immune checkpoint atezolizumab in combination with chemoradiation in locally advanced cervical cancer (ATEZOLACC trial)","volume":"35","author":"Chargari","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104944_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108052","article-title":"26O Maintenance dostarlimab after chemoradiation (CRT) for patients (pts) with high-risk locally advanced cervical cancer (LACC): GEICO 78-C\/ATOMICC randomised phase II trial","volume":"11","author":"Oaknin","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2026.104944_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108053","article-title":"27O Long-term survival outcomes and immune subgroup analyses in the COLIBRI study: induction nivolumab plus ipilimumab with immunotherapy maintenance (ICB) prior to and following chemoradiation (RT-CT) in locally advanced cervical cancer (LACC)","volume":"11","author":"Lobbedez","year":"2026","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104944_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-67646-z","article-title":"Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial","volume":"17","author":"Ray-Coquard","year":"2026","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104944_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41467-024-55200-2","article-title":"Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial","volume":"16","author":"Mayadev","year":"2025","journal-title":"Nat Commun"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:35:51Z","timestamp":1787657751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26004755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":7,"alternative-id":["S1048891X26004755"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104944","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does timing matter? Rethinking immunotherapy strategies in locally advanced cervical cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104944"}}